The companion category around GLP-1 treatment is unbuilt

Gali Artzi, partner and chief technology officer at the food-tech fund PeakBridge, argues in a June piece that GLP-1 treatment has moved women's metabolic health into mainstream clinical conversation faster than the care around it has been built. One in five women aged 50 to 64 in the United States has used a GLP-1.

• Body composition. She cites research putting 25 to 40% of the weight lost on a GLP-1 in lean mass rather than fat, and a 2026 study of 255 users at fracture risk, 92% of them women with an average age of 64, in which bone mineral density at the hip and femoral neck fell as much in the matched control group as in the treated one. What the authors tie the bone loss to is the weight loss itself, not the treatment.
• The off-ramp is where the gap sits. The STEP 1 trial extension found participants regained roughly two thirds of the weight lost within a year of stopping.
• The commercial read is retention. A 2026 Recurly benchmark across 76 million subscribers found 52% cancelled at least one service during the year, mostly through simple non-use.

The opportunity here is adjacency, not substitution. The treatment does its job. What is missing is everything around it: protein and micronutrient support matched to the phase of treatment, muscle and bone protection, and a designed step-down rather than a hard stop. A generic multivitamin and a monthly box do not meet a clinical need, and people drop what they cannot feel working. Whoever builds the companion product with real clinical grounding inherits a category that the treatment itself creates and does not serve. Worth holding in view while reading the numbers: the author's fund invests in exactly this space. (W Platform)